Cardiovascular diseases (CVDs) pose a significant threat to human health due to their high mor-tality and morbidity rates. Traditional drugs often have limited efficacy due to inherent constraints such as low bioavailability and notable side effects. As a highly regarded therapeutic strategy in recent years, Nanotechnology offers new perspectives and means for treating cardiovascular dis-eases. Especially, nanozyme-based targeted therapeutic drugs can specifically address the biological processes in areas affected by cardiovascular diseases, enabling precise treatment. Compared to traditional medicines, targeted nanozymes offer advantages such as high efficiency, specificity, controllability, and fewer side effects, leading to significant progress in the treatment of cardio-vascular diseases. This paper first introduces the design strategies for active targeting with nanozymes and the related mechanisms for treating cardiovascular diseases. It then outlines recent applications of targeted nanozymes in three typical cardiovascular diseases: ischemic stroke, ath-erosclerosis, and myocardial infarction. Finally, it discusses the challenges in applying targeted nanozymes and the prospects for future development.